Preparation of curcumin prodrugs and theirin vitro anti-tumor activities

Abstract

The curcumin prodrugs, which could be selectively activated in tumor cells, were prepared to establish a basis for the targeted chemotherapy for cancer. On the basis of the molecular structure of curcumin, the N-maleoyl-L-valine-curcumin (NVC), N-maleoyl- glycine-curcumin (NGC) were chemically synthesized and identified by IR and NMR spectroscopy. After treatment with these two prodrugs for 6–24 h, the rates of growth inhibition on human bladder cancer EJ cells and renal tubular epithelial (HKC) cells were detected by MTT colorimetry. Our results showed that after the treatment with 20 μmol/L–40 μmol/L NVC and NGC for 6–24 h, the growth inhibitory effects on EJ cells were 6.71%–65.13% (P<0.05), 10.96%–73.01% (P<0.05), respectively, in both dose- and time-dependent manners. When compared with the curcumin of same concentrations, the growth inhibitory effects of these two prodrugs on HKC cells were significantly decreased (P<0.01). It is concluded that activation of curcumin prodrugs via hydrolysis functions of cellular esterase could inhibit the growth activities of tumor cells, and reduce the side effects on normal diploid cells. This provided a novel strategy for further exploration of tumor-targeted chemotherapeutic drugs.

Keywords

curcumin / prodrug / tumor cells

References

[1] AggarwalB B, KumarA, BhartiA C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res, 2003, 23(1A): 363-363

[2] MahakunakornP, TohdaM, MurakamiY, et al. . Cytoprotective and cytotoxic effects of curcumin: dual action on H₂O₂-induced oxidative cell damage in NG108-15 cells. Biol Pharm Bull, 2003, 26(5): 725-725

[3] KuttanR, BhanumathyP, NirmalaK, et al. . Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett, 1985, 29(2): 197-197

[4] SoniK B, LahiriM, ChackradeoP, et al. . Protective effect of food additives on aflatoxin-induced mutagenicity and hepatocarcinogenicity. Cancer Lett, 1997, 115(2): 129-129

[5] ChauhanD P. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Des, 2002, 8(19): 1695-1695

[6] LinJ K, PanM H, Lin-ShiauS Y. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors, 2000, 13(1–4): 153-153

[7] ZhengL, TongQ, WuC. Growth-inhibitory effects of curcumin on ovary cancer cells and its mechanisms. J Huazhong Univ Sci Technolog (Med Sci), 2004, 24(1): 55-55

[8] ZhengL D, TongQ S, WuC H. Inhibitory effects of curcumin on apoptosis of human ovary cancer cell line A2780 and its molecular mechanism. Ai Zheng, 2002, 21(12): 1296-1296

[9] DennyW A. Prodrug strategies in cancer therapy. Eur J Med Chem, 2001, 36(7–8): 577-577

[10] Skrzypczak-JankunE, ZhouK, McCabeN P, et al. . Structure of curcumin in complex with lipoxygenase and its significance in cancer. Int J Mol Med, 2003, 12(1): 17-17

[11] MaZ, TaylorJ S. Nucleic acid-triggered catalytic drug release. Proc Natl Acad Sci USA, 2000, 97(21): 11159-11159